# Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study

> **NCT04231539** · NA · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Nicotine Dependence

## Interventions

- **DRUG:** Nicotine
- **DEVICE:** Vaporizer Device
- **DRUG:** Salt-HIgh Nicotine Unflavored (Product B)
- **DRUG:** Free-Low Nicotine Tobacco Flavored (Product C)
- **DRUG:** Salt-High Nicotine Tobacco Flavored (Product D)

## Key facts

- **NCT ID:** NCT04231539
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-18
- **Primary completion:** 2024-07-10
- **Final completion:** 2024-07-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04231539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04231539, "Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT04231539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*